← Back to Search

Alkylating agents

Chemotherapy for Biliary Cancers

Phase 2
Waitlist Available
Led By Bruce Giantonia, MD
Research Sponsored by Abramson Cancer Center of the University of Pennsylvania
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

This study evaluates the combination chemotherapy with gemcitabine, irinotecan and panitumumab in patients with advanced biliary cancer.

Eligible Conditions
  • Biliary Cancers
  • Bile Duct Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Side effects data

From 2014 Phase 2 trial • 35 Patients • NCT00948935
94%
rash
91%
anemia
80%
low calcium
80%
Hypoalbuminemia
77%
hypergylcemia
74%
fatigue
71%
diarrhea
71%
Platelet count decreased
71%
nausea
69%
Aspartate Aminotransferase (high)
66%
Hyponatremia
66%
constipation
66%
Leukocytosis
63%
Hypomagnesemia
63%
alkaline phosphatase (high)
57%
neutropenia
54%
alopecia
51%
Hypokalemia
49%
edema
49%
bilirubin (high)
46%
abdominal pain
46%
Alanine Aminotransferase (high)
40%
vomiting
37%
dehydration
37%
cough
37%
dyspnea
37%
anorexia
34%
insomnia
34%
hypoglymcemia
34%
dizziness
34%
back pain
31%
headache
31%
Metabolic Acidosis
29%
weight loss
29%
dry skin
26%
mucositis
26%
anxiety
23%
depression
23%
Hypophosphatemia
23%
lymphopenia
23%
fungal infection
20%
Fever
20%
high creatinine
14%
skin infection
14%
hypertension
14%
Dehydration
14%
taste alteration
14%
bloating
14%
flatulance
11%
Pulmonary Embolism
11%
heartburn
11%
Hyperkalemia
11%
night sweats
11%
Chills
11%
sore throat
11%
palpitations
11%
Thrombosis/thombus/embolism
11%
Neutrophil count decreased
11%
epistaxis
11%
ascites
11%
Upper Quadrant Pain
11%
thrush
11%
trichomegaly
11%
urinary tract infection
9%
blurred vision
9%
Obstruction, GI
9%
conjuctivitis
9%
Activated partial thromboplastin time prolonged
9%
rectal bleeding
9%
shortness of breath
9%
Hypernatremia
9%
sweating
9%
sepsis
9%
loss of appetite
9%
infusion reaction
9%
febrile neutropenia
9%
neutropenic fever
9%
cheliosis
9%
confusion
9%
dry mouth
6%
Diarrhea
6%
high calcium
6%
muscle cramping
6%
paronychia
6%
eye infection
6%
hiccups
6%
fracture
6%
small bowel obstruction
6%
syncope
6%
acne-form
6%
hypermagnesemia
6%
periorbital hair changes
6%
shoulder pain
6%
rhinitis
6%
congestion
6%
Dyspepsia
6%
erectile dysfunction
6%
deep vein thrombosis
6%
thrombosis
3%
finger infection
3%
Pericardial effusion
3%
hypertochosis
3%
hypoxia
3%
mouth sores
3%
Hyperesthesia
3%
light headedness
3%
numbness
3%
stent pain
3%
hypokalemia
3%
itching
3%
Confusion
3%
Encephalopathy
3%
Rash
3%
Febrile Neutropenia
3%
cellulitis
3%
cerebro-vascular ischemia
3%
Respiratory Arrest
3%
Hyperbilirubinemia
3%
Neurological Meningitis
3%
Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils (ANC <1.0 x 10e
3%
Hypercalcemia
3%
Syncope (fainting)
3%
Dyspnea
3%
Free Air
3%
sinus infection
3%
toe infection
3%
oral thrush
3%
hypertrichosis
3%
Hepatic pain
3%
Solar Plexis Pain
3%
Pain
3%
chronic obstructive pulmonary disease
3%
acidosis
3%
acute arterial occulsion LLE
3%
Infection with normal ANC or Grade 1 or 2 neutrophils
3%
dermal changes
3%
Infection with unknown ANC
3%
Pleural Effusion
3%
Body Aches
3%
Hepatic Encephalopathy
3%
herituism
3%
contact dermatitis
3%
decreased appetite
3%
dementia
3%
Flush
3%
Foot pain
3%
Palmar-plantar erythrodysesthesia syndrome
3%
Pleural effusion
3%
pneumonia
3%
Pruritis
3%
buttock pain
3%
septic shock
3%
sinus tachcardia
3%
Peripheral arterial ischemia
3%
Ear Pain
3%
reflux
3%
dry eye
3%
Renal Failure
3%
abdominal fullness
3%
somnolence
3%
Cardiac Arrhythmia
3%
hot flashes
3%
acute renal failure
3%
IV infiltration
3%
karatoses
3%
kidney stone
3%
leg cramps
3%
leg ulceration
3%
occular infection
3%
xerosis back
3%
Joint Pain
3%
rectal fissure
3%
renal failure
3%
respiratory infection
3%
rigors
3%
scratched cornea
3%
seasonal allergy
3%
sinus headache
3%
sinusitus
3%
upset stomach
3%
abdominal cramping
3%
Sepsis
3%
cold (respiratory)
3%
poison ivy
3%
dysphagia
3%
chest pain
3%
Abdomen NOS
3%
hand tremors
3%
carpal tunel
3%
dry cough
3%
Dysgeusia
3%
electrolyte imbalance
3%
elevated LTF
3%
exostosis
3%
fall
3%
floater
3%
flu-like symptoms
3%
Fatigue
3%
aches
3%
hematuria
3%
alkalosis
3%
allergic rhinitis
3%
tape allergy
3%
amylase (high)
3%
ascending cholangitis
3%
atelectasis
3%
belching
3%
hemorrhoids
3%
hoarseness
3%
forearm pain
3%
Scapula pain
3%
thrombocytosis
3%
Hypertriglyceridemia
3%
upper respiratory congestion
3%
vessel injury
3%
yeast infection
100%
80%
60%
40%
20%
0%
Study treatment Arm
Chemotherapy

Trial Design

1Treatment groups
Experimental Treatment
Group I: ChemotherapyExperimental Treatment1 Intervention
Gemcitabine (Days 1, 8), irinotecan (days 1, 8) and panitumumab (day 1) every 3 weeks as a cycle. Continue until disease progression or unacceptable toxicities.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Panitumumab
FDA approved

Find a Location

Who is running the clinical trial?

Abramson Cancer Center of the University of PennsylvaniaLead Sponsor
359 Previous Clinical Trials
105,851 Total Patients Enrolled
Abramson Cancer Center at Penn MedicineLead Sponsor
403 Previous Clinical Trials
155,960 Total Patients Enrolled
Bruce Giantonia, MDPrincipal InvestigatorAbramson CC
~2 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top